Published: Dec. 14, 2020


Vitro3D is a company hoping to revolutionize the cancer drug discovery process. Cancer drug development is a long, risky and expensive process because pharmaceutical companies waste billions of dollars in research and development. They test drugs that are doomed to fail, while also dismissing viable drugs. A key pain point is that the current gold standard for preclinical drug screening doesn’t accurately represent breast tumor tissue, leading to conflicting results, preclinical delays, and late-stage clinical failures.


Vitro 3D relieves this pain point by providing a spatially controlled 3D printed platform that mimics the living environment allowing for the detection of viable drugs earlier in the screening process. Ultimately this means that companies using our technology can fail faster and succeed more with lower risk and lower cost. The global 3D cell culture market size was valued at USD 1.4 billion in 2019 and is anticipated to witness a CAGR of 11.3% ensuring a well-timed entry into the market. 


  • More accurately reflects the living environment
  • Shorter drug discovery timelines 
  • Greater clinical trial efficacy


  • Cell culture/drug discovery


Vitro3D is looking for funding and partnershhips to continue to develop their product and build upon their existing commercialization momentum.

vitro 3d


Nicole Forsberg: